Education
About Us
Working with TipRanks
Follow Us
TELA Bio (TELA)
NASDAQ:TELA
TELA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.86 - $3.26
Previous CloseN/A
Volume34.27K
Average Volume (3M)93.65K
Market Cap
$64.18M
Enterprise Value$94.93M
Total Cash (Recent Filing)$34.98M
Total Debt (Recent Filing)$41.90M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Nov 05, 2025EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding39,616,440
10 Day Avg. Volume77,175
30 Day Avg. Volume93,653
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.48
Enterprise Value/Revenue1.26
Enterprise Value/Gross Profit1.87
Enterprise Value/Ebitda-2.73
Forecast
1Y Price Target
$6.50Price Target Upside311.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Financial PerformanceReaching the milestone of $100M in revenues brings the company closer to profitability and increases the tangibility of TELA as a take-out candidate.
Growth OpportunitiesNew products like inguinal hernia and Liquifix have been successful since their launch, providing TELA opportunities in high-volume procedures.
Leadership And ManagementThe appointment of Jeff Blizard, who brings extensive leadership experience from Abiomed, is seen as a positive move for TELA's growth strategy.
Bears Say
Financial ChallengesDespite controlling some costs, the operating loss was higher than anticipated, suggesting financial challenges.
Need For FinancingThe company may need another round of financing to fund operations, which could negatively impact the stock.
Sales And Workforce ChallengesThe departure of 11 of 69 high-performing territory managers led to a significant drop in sales.
TELA Bio News
TELA FAQ
What was TELA Bio’s price range in the past 12 months?
TELA Bio lowest stock price was $0.86 and its highest was $3.26 in the past 12 months.
What is TELA Bio’s market cap?
TELA Bio’s market cap is $64.18M.
When is TELA Bio’s upcoming earnings report date?
TELA Bio’s upcoming earnings report date is Nov 05, 2025 which is in 52 days.
How were TELA Bio’s earnings last quarter?
TELA Bio released its earnings results on Aug 11, 2025. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.176 by -$0.044.
Is TELA Bio overvalued?
According to Wall Street analysts TELA Bio’s price is currently Undervalued.
Does TELA Bio pay dividends?
TELA Bio does not currently pay dividends.
What is TELA Bio’s EPS estimate?
TELA Bio’s EPS estimate is -0.19.
How many shares outstanding does TELA Bio have?
TELA Bio has 39,616,440 shares outstanding.
What happened to TELA Bio’s price movement after its last earnings report?
TELA Bio reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.176. Following the earnings report the stock price went down -13.978%.
Which hedge fund is a major shareholder of TELA Bio?
Currently, no hedge funds are holding shares in TELA
TELA Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.50 (311.39% Upside)
$6.50 (311.39% Upside)
Blogger Sentiment
Bullish
TELA Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 6.6%
Last 30 Days ▲ 6.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.23%
12-Months-Change
Fundamentals
Return on Equity
-676.41%
Trailing 12-Months
Asset Growth
12.18%
Trailing 12-Months
Company Description
TELA Bio
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
TELA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth, particularly in the OviTex and LIQUIFIX portfolios, as well as successful expansion in the European market. However, the company still faces challenges with its net loss and slight increase in sales and marketing expenses. Overall, the positive achievements outweighed the challenges.View all TELA earnings summariesTELA Stock 12 Month Forecast
Average Price Target
$6.50
▲(311.39% Upside)
Technical Analysis
Ownership Overview
13.14% Insiders
7.35% Mutual Funds
50.59% Other Institutional Investors
24.70% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---